CoChat
Sign Up
Cited by 2,762Erythropoietin and Anemia TreatmentDialysis and Renal Disease ManagementBiosimilars and Bioanalytical Methods

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease

Open access
Singh, Ajay K., Szczech, Lynda, Tang, Kezhen L., Barnhart, Huiman, Sapp, Shelly, Wolfson, Marsha, Reddan, Donal·2006·New England Journal of Medicine
DOI 10.1056/nejmoa065485
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin deficiency. Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia associated with this condition. However, the optimal level of hemoglobin correction is not defined. METHODS: In this open-label trial, we studied 1432 patients with chronic kidney disease, 715 of whom were randomly assigned to receive a dose of epoetin alfa targeted to achieve a hemoglobin level of 13.5 g per deciliter and 717 of whom were assigned to receive a dose targeted to achieve a level of 11.3 g per deciliter. The median study duration was 16 months. The primary end point was a composite of death, myocardial infarction, hospitalization for congestive heart failure (without renal replacement therapy), and stroke. RESULTS: A total of 222 composite events occurred: 125 events in the high-hemoglobin group, as compared with 97 events in the low-hemoglobin group (hazard ratio, 1.34; 95% confidence interval, 1.03 to 1.74; P=0.03). There were 65 deaths (29.3%), 101 hospitalizations for congestive heart failure (45.5%), 25 myocardial infarctions (11.3%), and 23 strokes (10.4%). Seven patients (3.2%) were hospitalized for congestive heart failure and myocardial infarction combined, and one patient (0.5%) died after having a stroke. Improvements in the quality of life were similar in the two groups. More patients in the high-hemoglobin group had at least one serious adverse event. CONCLUSIONS: The use of a target hemoglobin level of 13.5 g per deciliter (as compared with 11.3 g per deciliter) was associated with increased risk and no incremental improvement in the quality of life. (ClinicalTrials.gov number, NCT00211120 [ClinicalTrials.gov].).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa065485

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 1

  1. Strippoli GF, 2003, Cochrane Database Syst Rev, 1, CD003967

Cited by

Sorted by citations

Items 901–1,000 of 1,002

Related

See all

Metadata

Authors
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D.
Affiliations
  • Brigham and Women's Hospital (US)
  • Duke Medical Center (US)
  • Duke University (US)
  • Duke Clinical Research Institute (US)
  • Ollscoil na Gaillimhe – University of Galway (IE)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2006-11-16
Volume
355
Issue
20
Pages
2085-2098
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa065485
OpenAlex
W2040029744
Cited by
2,762
References
32
Citations by year
2026: 57 · 2025: 64 · 2024: 73 · 2023: 95 · 2022: 95 · 2021: 116 · 2020: 121 · 2019: 116 · 2018: 92 · 2017: 101 · 2016: 108 · 2015: 114 · 2014: 155 · 2013: 176 · 2012: 182
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Keywords
epoetin alfa, chronic kidney disease, anemia of chronic kidney disease, hemoglobin target, erythropoietin deficiency, cardiovascular events, congestive heart failure, myocardial infarction, stroke, mortality, quality of life, adverse events
MeSH terms
Epoetin Alfa, Aged, Anemia, Erythropoietin, Female, Glomerular Filtration Rate, Heart Failure, Hematinics, Hemoglobins, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Recombinant Proteins, Survival Analysis, Stroke, Renal Insufficiency, Chronic, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review